These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11460982)

  • 21. Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality.
    Roussel JC; Baron O; Périgaud C; Bizouarn P; Pattier S; Habash O; Mugniot A; Petit T; Michaud JL; Heymann MF; Treilhaud M; Trochu JN; Gueffet JP; Lamirault G; Duveau D; Despins P
    J Heart Lung Transplant; 2008 May; 27(5):486-93. PubMed ID: 18442713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
    Valantine H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeated immune and non immune insults to the graft after heart transplantation.
    Crudele V; Picascia A; Infante T; Grimaldi V; Maiello C; Napoli C
    Immunol Lett; 2011 Dec; 141(1):18-27. PubMed ID: 21803073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart transplantation in children: clinical outcome during the early postoperative period.
    Azeka E; Auler JO; Marcial MB; Fumagalli F; Ramires JA
    Pediatr Transplant; 2005 Aug; 9(4):491-7. PubMed ID: 16048602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocardial HLA-G reliably indicates a low risk of acute cellular rejection in heart transplant recipients.
    Sheshgiri R; Rouas-Freiss N; Rao V; Butany J; Ramzy D; Krawice-Radanne I; Ross HJ; Carosella ED; Delgado DH
    J Heart Lung Transplant; 2008 May; 27(5):522-7. PubMed ID: 18442718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factor analysis in pediatric heart transplantation.
    Tjang YS; Stenlund H; Tenderich G; Hornik L; Bairaktaris A; Körfer R
    J Heart Lung Transplant; 2008 Apr; 27(4):408-15. PubMed ID: 18374877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection.
    Pescovitz MD
    Clin Transplant; 2006; 20(1):48-54. PubMed ID: 16556153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac transplantation in the United States: an analysis of the UNOS registry.
    Everly MJ
    Clin Transpl; 2008; ():35-43. PubMed ID: 19708444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The University of California at Los Angeles heart transplantation experience.
    Kobashigawa JA; Laks H; Wu G; Patel J; Moriguchi J; Hamilton M; Fonarow G; Fishbein M; Ardehali A
    Clin Transpl; 2005; ():173-85. PubMed ID: 17424734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart transplantation across antibodies against human leukocyte antigen and ABO-post-transplant follow-up of donor reactive antibodies.
    Bućin D; Johansson S; Lindberg LO
    Xenotransplantation; 2006 Mar; 13(2):101-4. PubMed ID: 16623800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unique aspects of rejection and tolerance in liver transplantation.
    Knechtle SJ; Kwun J
    Semin Liver Dis; 2009 Feb; 29(1):91-101. PubMed ID: 19235662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The University of Vienna experience in heart transplantation.
    Zuckermann A; Bohdjalian A; Deviatko E; Dunkler D; Rödler S; Ehrlich M; Wieselthaler G; Pacher R; Bunzel B; Wollenek G; Laczkovics A; Laufer G; Wolner E; Grimm M
    Clin Transpl; 2002; ():229-42. PubMed ID: 12971454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first year post-heart transplantation: use of immunosuppressive drugs and early complications.
    Sulemanjee NZ; Merla R; Lick SD; Aunon SM; Taylor M; Manson M; Czer LS; Schwarz ER
    J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):13-31. PubMed ID: 18287587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric heart transplantation.
    Boucek MM; Pietra BA
    Curr Opin Cardiol; 1995 Mar; 10(2):223-8. PubMed ID: 7787289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
    Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
    Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?
    Higgins R; Kirklin JK; Brown RN; Rayburn BK; Wagoner L; Oren R; Miller L; Flattery M; Bourge RC;
    J Heart Lung Transplant; 2005 Apr; 24(4):392-400. PubMed ID: 15797738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.